JP2021521851A5 - - Google Patents
Info
- Publication number
- JP2021521851A5 JP2021521851A5 JP2020560355A JP2020560355A JP2021521851A5 JP 2021521851 A5 JP2021521851 A5 JP 2021521851A5 JP 2020560355 A JP2020560355 A JP 2020560355A JP 2020560355 A JP2020560355 A JP 2020560355A JP 2021521851 A5 JP2021521851 A5 JP 2021521851A5
- Authority
- JP
- Japan
- Prior art keywords
- gene therapy
- therapy vector
- vector according
- disease
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024068431A JP2024119788A (ja) | 2018-04-30 | 2024-04-19 | 遺伝子治療構築物及び使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664741P | 2018-04-30 | 2018-04-30 | |
| US62/664,741 | 2018-04-30 | ||
| US201862688640P | 2018-06-22 | 2018-06-22 | |
| US62/688,640 | 2018-06-22 | ||
| US201862744068P | 2018-10-10 | 2018-10-10 | |
| US62/744,068 | 2018-10-10 | ||
| PCT/US2019/030076 WO2019213180A1 (en) | 2018-04-30 | 2019-04-30 | Gene therapy constructs and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024068431A Division JP2024119788A (ja) | 2018-04-30 | 2024-04-19 | 遺伝子治療構築物及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521851A JP2021521851A (ja) | 2021-08-30 |
| JP2021521851A5 true JP2021521851A5 (cg-RX-API-DMAC7.html) | 2022-05-11 |
| JP7749322B2 JP7749322B2 (ja) | 2025-10-06 |
Family
ID=66669057
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560355A Active JP7749322B2 (ja) | 2018-04-30 | 2019-04-30 | 遺伝子治療構築物及び使用方法 |
| JP2024068431A Withdrawn JP2024119788A (ja) | 2018-04-30 | 2024-04-19 | 遺伝子治療構築物及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024068431A Withdrawn JP2024119788A (ja) | 2018-04-30 | 2024-04-19 | 遺伝子治療構築物及び使用方法 |
Country Status (16)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202344691A (zh) * | 2018-04-30 | 2023-11-16 | 美商阿米庫斯醫療股份有限公司 | 基因治療構築體及使用方法 |
| JP7577650B2 (ja) | 2018-10-10 | 2024-11-05 | アミカス セラピューティックス インコーポレイテッド | ジスルフィド結合により安定したポリペプチド組成物及びその使用方法 |
| JP2022552254A (ja) * | 2019-10-10 | 2022-12-15 | アミカス セラピューティックス インコーポレイテッド | バリアントigf2構築体 |
| WO2021102107A1 (en) * | 2019-11-19 | 2021-05-27 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders |
| EP4081241A4 (en) | 2019-12-24 | 2024-05-01 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND USES THEREOF |
| JP7443761B2 (ja) | 2019-12-25 | 2024-03-06 | 東洋紡エムシー株式会社 | 中空糸膜モジュール |
| EP4149519A4 (en) * | 2020-05-14 | 2024-06-12 | The Trustees of The University of Pennsylvania | COMPOSITIONS FOR THE TREATMENT OF POMPE DISEASE |
| BR112023001456A2 (pt) | 2020-07-27 | 2023-04-11 | Voyager Therapeutics Inc | Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase |
| US20230285596A1 (en) | 2020-07-27 | 2023-09-14 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| CN111733174B (zh) * | 2020-08-07 | 2021-02-09 | 北京大学第三医院(北京大学第三临床医学院) | 一种分离的核酸分子及其用途 |
| WO2022081794A1 (en) * | 2020-10-15 | 2022-04-21 | Tavotek Biotherapeutics (Hong Kong) Limited | Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof |
| US20220153869A1 (en) * | 2020-11-16 | 2022-05-19 | Tavotek Biotherapeutics (Hong Kong) Limited | Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof |
| WO2022119890A1 (en) | 2020-12-01 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
| EP4359425B1 (en) | 2021-06-21 | 2026-08-05 | Juvena Therapeutics, Inc. | Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury |
| US20250034533A1 (en) * | 2021-11-12 | 2025-01-30 | Amicus Therapeutics, Inc. | Compositions And Methods For Treating Mucopolysaccharidosis IIIA |
| US20250049955A1 (en) | 2021-11-17 | 2025-02-13 | Voyager Therapeutics, Inc. | Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| US20260216373A1 (en) | 2023-01-13 | 2026-07-30 | Amicus Therapeutics, Inc. | Gene Therapy Constructs for the Treatment of Pompe Disease |
| AU2023427408A1 (en) | 2023-02-02 | 2025-09-04 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2024226761A2 (en) | 2023-04-26 | 2024-10-31 | Voyager Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| WO2026006281A1 (en) * | 2024-06-24 | 2026-01-02 | Remedium Bio, Inc. | A system for delivering genetic material subcutaneously with elements enabling subsequent post-treatment identification, localization, quantification, evaluation, or targeting for up- and/or down-titration |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087164A (en) * | 1997-10-03 | 2000-07-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| EP1118334A1 (en) | 2000-01-11 | 2001-07-25 | Aventis Behring Gesellschaft mit beschränkter Haftung | Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| EP1436316B1 (en) | 2001-04-30 | 2008-01-23 | ZyStor Therapeutics , Inc. | Subcellular targeting of therapeutic proteins |
| WO2003032913A2 (en) * | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| DE10237639A1 (de) * | 2002-08-13 | 2004-02-26 | Martin-Luther-Universität Halle-Wittenberg | Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle |
| PT1587923E (pt) | 2003-01-22 | 2011-12-07 | Univ Duke | Construções melhoradas para a expressão de polipéptidos lisossomais |
| JP4979067B2 (ja) * | 2003-05-01 | 2012-07-18 | ジェンザイム・コーポレーション | 神経代謝性疾患についての遺伝子治療 |
| GB0314856D0 (en) | 2003-06-25 | 2003-07-30 | Unitargeting Res As | Protein expression system |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| DE602005020745D1 (de) | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| ES2242542B1 (es) * | 2004-04-30 | 2006-12-16 | Consejo Superior De Investigaciones Cientificas | Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv). |
| WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
| CN1903374A (zh) * | 2005-07-27 | 2007-01-31 | 中国人民解放军军事医学科学院生物医学分析中心 | 大肠杆菌在制备肿瘤诊断或治疗药物中的用途 |
| AU2007322123A1 (en) | 2006-11-13 | 2008-05-29 | Biomarin Pharmaceutical Inc. | Methods for treating Pompe disease |
| WO2009137721A2 (en) | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| PL3912643T3 (pl) | 2009-02-13 | 2023-01-23 | Immunomedics Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
| HRP20181315T1 (hr) | 2010-11-22 | 2018-10-19 | Amicus Therapeutics, Inc. | Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina |
| US9662375B2 (en) * | 2010-11-30 | 2017-05-30 | Orphazyme Aps | Methods for increasing intracellular activity of Hsp70 |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| EP2687597B1 (en) | 2011-03-16 | 2018-12-26 | Amano Enzyme Inc. | Modified alpha-glucosidase and applications of same |
| LT2714752T (lt) | 2011-05-27 | 2018-03-12 | Amicus Therapeutics, Inc. | Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui |
| US9387236B2 (en) * | 2011-06-10 | 2016-07-12 | Prothera Inc. | Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases |
| ES2679374T3 (es) * | 2012-11-27 | 2018-08-24 | Biomarin Pharmaceutical Inc. | Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas |
| EP2976092B1 (en) * | 2013-03-15 | 2020-04-22 | Amicus Therapeutics, Inc. | Chemical crosslinkers |
| WO2015060722A1 (en) * | 2013-10-24 | 2015-04-30 | Uniqure Ip B.V. | Aav-5 pseudotyped vector for gene therapy for neurological diseases |
| WO2015085238A1 (en) | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
| TW202344691A (zh) * | 2018-04-30 | 2023-11-16 | 美商阿米庫斯醫療股份有限公司 | 基因治療構築體及使用方法 |
| JP2022552254A (ja) * | 2019-10-10 | 2022-12-15 | アミカス セラピューティックス インコーポレイテッド | バリアントigf2構築体 |
-
2019
- 2019-04-30 TW TW112122938A patent/TW202344691A/zh unknown
- 2019-04-30 SG SG11202010533WA patent/SG11202010533WA/en unknown
- 2019-04-30 CN CN201980029113.5A patent/CN112513071A/zh active Pending
- 2019-04-30 CA CA3098674A patent/CA3098674A1/en active Pending
- 2019-04-30 TW TW108115137A patent/TWI808169B/zh not_active IP Right Cessation
- 2019-04-30 BR BR112020021962-2A patent/BR112020021962A2/pt not_active IP Right Cessation
- 2019-04-30 US US16/399,979 patent/US10874750B2/en active Active
- 2019-04-30 KR KR1020207033891A patent/KR20210005154A/ko not_active Ceased
- 2019-04-30 WO PCT/US2019/030076 patent/WO2019213180A1/en not_active Ceased
- 2019-04-30 AU AU2019261982A patent/AU2019261982A1/en not_active Abandoned
- 2019-04-30 MX MX2020011514A patent/MX2020011514A/es unknown
- 2019-04-30 EP EP19727170.3A patent/EP3788064A1/en active Pending
- 2019-04-30 JP JP2020560355A patent/JP7749322B2/ja active Active
-
2020
- 2020-10-29 CL CL2020002809A patent/CL2020002809A1/es unknown
- 2020-10-30 PH PH12020551818A patent/PH12020551818A1/en unknown
- 2020-11-05 ZA ZA2020/06905A patent/ZA202006905B/en unknown
- 2020-11-27 CO CONC2020/0014729A patent/CO2020014729A2/es unknown
- 2020-12-18 US US17/127,001 patent/US11491243B2/en active Active
-
2022
- 2022-11-07 US US18/053,160 patent/US20230233711A1/en active Pending
-
2024
- 2024-04-19 JP JP2024068431A patent/JP2024119788A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10202591B2 (en) | Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders | |
| IL273439B2 (en) | Fusion proteins involving enzyme replacement in enzyme therapy | |
| JP2022512689A5 (cg-RX-API-DMAC7.html) | ||
| KR20210005154A (ko) | 유전자 요법 작제물 및 사용 방법 | |
| AU2003215869B2 (en) | Hybrid and single chain meganucleases and use thereof | |
| WO2014130722A1 (en) | Methods and compositions for treatment of forbes-cori disease | |
| IL276464B1 (en) | Methods and compositions for administering therapeutic protein | |
| JP2021512899A5 (cg-RX-API-DMAC7.html) | ||
| JP2022519507A5 (cg-RX-API-DMAC7.html) | ||
| JP2022552254A5 (cg-RX-API-DMAC7.html) | ||
| KR20250021616A (ko) | 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 | |
| JP2021507705A (ja) | 新規な構造を有する治療学的酵素融合タンパク質及びその用途 | |
| JP2022552254A (ja) | バリアントigf2構築体 | |
| JP2007525997A (ja) | アドザイムおよびその使用法 | |
| JP2005537032A (ja) | アドザイムおよびその用途 | |
| WO2015009052A1 (ko) | 하이브리드 면역글로불린 fc와 효소의 융합단백질 | |
| KR20150132126A (ko) | 화학적 가교결합제 | |
| Yoon et al. | Cloning and cytotoxicity of fusion proteins of EGF and angiogenin | |
| Das et al. | Multifunctional activities of human fibroblast 34-kDa hyaluronic acid-binding protein | |
| US20080025995A1 (en) | Cross-Placenta Delivery System | |
| AU2023210789A1 (en) | Iga protease truncation, fusion protein comprising iga protease truncation, and use thereof | |
| CA2529553A1 (en) | Ribonucleases and methods of making them recombinantly | |
| US20240318157A1 (en) | Neurotensin Variants And Tagged Proteins Comprising Neurotensin Or Sortilin Propeptide | |
| KR101582655B1 (ko) | 광활성 메티오닌 모사체 표지 단백질 생합성을 위한 메티오닐 tRNA 합성효소 변이체 | |
| WO2025264978A3 (en) | Recombinant alpha-galactosidase a proteins and gene therapy |